STOCK TITAN

Neurocrine Biosciences Inc SEC Filings

NBIX NASDAQ

Welcome to our dedicated page for Neurocrine Biosciences SEC filings (Ticker: NBIX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Decoding Neurocrine Biosciences’ SEC disclosures can feel like a clinical trial in itself—hundreds of pages of neurology jargon, R&D cost tables, and patent-expiry timelines bury crucial signals such as INGREZZA revenue momentum and cash runway for its congenital adrenal hyperplasia program. If you have ever asked, “Where can I find Neurocrine Biosciences’ quarterly earnings report 10-Q filing?” or “How do I track NBIX insider trading Form 4 transactions in real time?”, you know the challenge.

Stock Titan’s AI does the heavy lifting. Our engine reads every new 10-K, 10-Q, 8-K, proxy and S-8 the moment it lands on EDGAR, then translates complex language into clear takeaways. Instead of combing through footnotes, you receive concise explanations, cash-flow highlights, and instant alerts on Neurocrine Biosciences Form 4 insider transactions real-time. Key documents and what you’ll learn are grouped for fast access:

  • Annual report 10-K simplified – spot INGREZZA sales trends, R&D tax credits and patent life in minutes.
  • Quarterly earnings report 10-Q filing – compare sequential revenue, trial spend and liquidity ratios without crunching spreadsheets.
  • 8-K material events explained – understand clinical-trial readouts or FDA updates as soon as they post.
  • Executive stock transactions Form 4 – monitor buying or selling that may signal management’s conviction.
  • Proxy statement executive compensation – review incentive structures tied to pipeline milestones.

Whether you need understanding Neurocrine Biosciences SEC documents with AI before the market opens or a deeper dive into NBIX earnings report filing analysis for strategy meetings, Stock Titan delivers complete, continuously updated coverage—no biotech PhD required.

Rhea-AI Summary

Robinhood Markets, Inc. (HOOD) has filed a Form 144 indicating the intended sale of 250,000 common shares with an estimated aggregate market value of $23.6 million. The shares are slated to be sold through Morgan Stanley Smith Barney LLC on or about 07 July 2025 on the NASDAQ.

The filing lists 767,047,021 shares outstanding; the contemplated transaction therefore represents roughly 0.03 % of the float, suggesting limited dilution or trading-volume impact. The notice also discloses that 750,000 shares were sold on 01 July 2025 for $69.95 million under a Rule 10b5-1 plan attributed to Vladimir Tenev.

  • The current sale plus the earlier disposal totals 1.0 million shares, generating about $93.5 million for the insider within a single week.
  • The seller affirms awareness of no undisclosed adverse information, and reliance on a written 10b5-1 plan mitigates insider-trading risk.

While purely administrative and not a guarantee of execution, the filing signals continued insider selling activity. Investors often watch such patterns for sentiment clues, even when the share count is immaterial relative to the company’s overall capitalization.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Filing
Rhea-AI Summary

GitLab Inc. (NASDAQ: GTLB) has filed a Form 144 disclosing the proposed sale of 1,214 shares of its Class A common stock under Rule 144. The shares, valued at roughly $55,249, account for less than 0.001 % of the company’s approximately 146.1 million shares outstanding, making the transaction immaterial to GitLab’s overall float and market liquidity.

The seller acquired the stock as restricted stock units (RSUs) on 27 June 2025 and intends to execute the sale through Morgan Stanley Smith Barney LLC on or after 2 July 2025. No additional sales by this filer have occurred in the past three months. The notice states that the filer is unaware of any non-public adverse information, suggesting this is a routine liquidity event rather than a signal of strategic change.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other

FAQ

What is the current stock price of Neurocrine Biosciences (NBIX)?

The current stock price of Neurocrine Biosciences (NBIX) is $133.51 as of July 9, 2025.

What is the market cap of Neurocrine Biosciences (NBIX)?

The market cap of Neurocrine Biosciences (NBIX) is approximately 12.7B.

What is the core focus of Neurocrine Biosciences Inc?

The company focuses on the discovery, development, and commercialization of innovative treatments for neurological, neuroendocrine, and neuropsychiatric disorders.

Which therapeutic areas does Neurocrine primarily target?

Its primary areas include movement disorders such as tardive dyskinesia and Huntington's disease chorea, as well as endocrine-related conditions like congenital adrenal hyperplasia and other hormonal imbalances.

How does Neurocrine differentiate itself in the biopharmaceutical industry?

Neurocrine differentiates itself through a deep scientific understanding of brain and body interconnections, rigorous R&D processes, and a tailored focus on under-addressed conditions with significant unmet needs.

What role does clinical research play in Neurocrine's strategy?

Clinical research is at the heart of their strategy, ensuring that each product is backed by robust clinical data and validated through well-designed studies, which bolsters the safety and efficacy profiles of their treatments.

Does Neurocrine have a diversified product portfolio?

Yes, the company has a diverse portfolio that includes FDA-approved treatments for various movement and endocrine disorders, alongside a robust pipeline of compounds in mid- to late-phase clinical development.

How are Neurocrine's therapies developed?

Their therapies are developed using a research-driven approach that integrates advanced neuroscience and clinical expertise, focusing on precise mechanisms such as selective inhibition of specific transporters involved in disease pathology.

Who are the typical beneficiaries of Neurocrine's treatments?

Patients suffering from complex neurological and endocrine disorders who have few effective treatment options are the primary beneficiaries of Neurocrine’s innovative therapies.

How does Neurocrine ensure the quality and reliability of its products?

Quality is ensured through rigorous preclinical and clinical testing, adherence to strict regulatory standards, and a commitment to evidence-based research, which builds strong trust in their treatments.
Neurocrine Biosciences Inc

NASDAQ:NBIX

NBIX Rankings

NBIX Stock Data

12.67B
96.88M
1.02%
97.9%
3.24%
Drug Manufacturers - Specialty & Generic
Biological Products, (no Disgnostic Substances)
Link
United States
SAN DIEGO